Real-time index price for PHLX Aussie Dollar (XDA), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Novo also stated that Hims & Hers is duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs. Last week, the U.S. Food and Drug Administration ...

Real-time index price for Nasdaq Health Care Index (IXHC), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

To say that pharmaceutical giant Novo Nordisk (NYSE: NVO) has had a tumultuous relationship with telehealth company Hims & Hers Health (NYSE: HIMS) in the past year would be a bit of an understatement ...

Hims & Hers (HIMS) has taken a beating, with the stock down roughly 70% from its $70 peak and now trading below $21 per share. But the story's changing. After the company's Novo Nordisk (NVO) deal and ...

Hims & Hers Health (HIMS) said that it has begun selling Novo Nordisk (NVO) GLP-1 medicines Wegovy (semaglutide) and Ozempic (semaglutide), which are indicated for weight loss and type 2 diabetes. All ...

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings report. The move caps a ...